phosphorylcholine has been researched along with Myocardial Infarction in 15 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to assess the diagnostic accuracy of autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and to phosphorylcholine (anti-PC IgM) for non-ST segment elevation acute myocardial infarction (NSTEMI) and to explore their potential prognostic value." | 7.81 | Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction. ( Grueter, D; Haaf, P; Jaeger, C; Montecucco, F; Mueller, C; Pagano, S; Reichlin, T; Rubini Gimenez, M; Twerenbold, R; Virzi, J; Vuilleumier, N; Wildi, K, 2015) |
| "To explore the diagnostic accuracies of anti-apolipoproteinA-1 (anti-ApoA-1) IgG and anti-phosphorylcholine (anti-PC) IgM alone, expressed as a ratio (anti-ApoA-1 IgG/anti-PC IgM), and combined with the Thrombolysis In Myocardial Infarction (TIMI) score for non-ST-segment elevation myocardial infarction (NSTEMI) (NSTEMI-TIMI score) to create a new diagnostic algorithm - the Clinical Autoantibody Ratio (CABR) score - for the diagnosis of NSTEMI and subsequent cardiac troponin I (cTnI) elevation in patients with acute chest pain (ACP)." | 7.78 | Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. ( Hochstrasser, D; Keller, PF; Mach, F; Pagano, S; Roux-Lombard, P; Rutschmann, OT; Sigaud, P; Vuilleumier, N, 2012) |
| "The aim of this pilot study was to evaluate the safety and efficacy of the BiodivYsio phosphorylcholine-coated stent in the primary treatment of acute myocardial infarction." | 7.71 | Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction. ( Bonatti, R; Butti, E; Ferrari, G; Galli, M; Mameli, S; Pagano, A; Politi, A; Prati, F; Sommariva, L; Zerboni, S, 2001) |
| " We aimed to assess the diagnostic accuracy of autoantibodies to apolipoprotein A-1 (anti-apoA-1 IgG) and to phosphorylcholine (anti-PC IgM) for non-ST segment elevation acute myocardial infarction (NSTEMI) and to explore their potential prognostic value." | 3.81 | Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction. ( Grueter, D; Haaf, P; Jaeger, C; Montecucco, F; Mueller, C; Pagano, S; Reichlin, T; Rubini Gimenez, M; Twerenbold, R; Virzi, J; Vuilleumier, N; Wildi, K, 2015) |
| "To explore the diagnostic accuracies of anti-apolipoproteinA-1 (anti-ApoA-1) IgG and anti-phosphorylcholine (anti-PC) IgM alone, expressed as a ratio (anti-ApoA-1 IgG/anti-PC IgM), and combined with the Thrombolysis In Myocardial Infarction (TIMI) score for non-ST-segment elevation myocardial infarction (NSTEMI) (NSTEMI-TIMI score) to create a new diagnostic algorithm - the Clinical Autoantibody Ratio (CABR) score - for the diagnosis of NSTEMI and subsequent cardiac troponin I (cTnI) elevation in patients with acute chest pain (ACP)." | 3.78 | Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. ( Hochstrasser, D; Keller, PF; Mach, F; Pagano, S; Roux-Lombard, P; Rutschmann, OT; Sigaud, P; Vuilleumier, N, 2012) |
| "The aim of this pilot study was to evaluate the safety and efficacy of the BiodivYsio phosphorylcholine-coated stent in the primary treatment of acute myocardial infarction." | 3.71 | Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction. ( Bonatti, R; Butti, E; Ferrari, G; Galli, M; Mameli, S; Pagano, A; Politi, A; Prati, F; Sommariva, L; Zerboni, S, 2001) |
| "Phosphorylcholine is a pro-inflammatory epitope exposed on apoptotic cells, and phosphorylcholine monoclonal immunoglobulin (Ig)G antibodies (PC-mAb) have anti-inflammatory properties." | 1.62 | Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response. ( Atsma, DE; de Jong, RCM; de Vries, MR; Jukema, JW; Pettersson, K; Pluijmert, NJ; Quax, PHA, 2021) |
| " This study aimed to investigate the feasibility of using focused pharmacovigilance for VL (VLPV) in Bangladesh's National Kala-azar Elimination Programme for the early detection and prevention of expected and unexpected adverse drug reactions (ADRs)." | 1.48 | Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. ( Ahuja, V; Ghosh, P; Haque, R; Hossain, AFMA; Hossain, MA; Hossain, MS; Kumar, A; Mahshin, M; Maruf, S; Mondal, D; Shamsuzzaman, AKM; Sharma, A; Sharma, V, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taleb, A | 1 |
| Willeit, P | 1 |
| Amir, S | 1 |
| Perkmann, T | 1 |
| Kozma, MO | 1 |
| Watzenböck, ML | 1 |
| Binder, CJ | 1 |
| Witztum, JL | 1 |
| Tsimikas, S | 1 |
| Li, Y | 1 |
| Qi, Q | 1 |
| Yang, WC | 1 |
| Zhang, TL | 1 |
| Lu, CC | 1 |
| Yao, YJ | 1 |
| Kong, WH | 1 |
| Zhao, J | 1 |
| Pluijmert, NJ | 1 |
| de Jong, RCM | 1 |
| de Vries, MR | 1 |
| Pettersson, K | 1 |
| Atsma, DE | 1 |
| Jukema, JW | 1 |
| Quax, PHA | 1 |
| Lewis, AL | 1 |
| Stratford, PW | 1 |
| Hossain, MS | 1 |
| Kumar, A | 1 |
| Hossain, AFMA | 1 |
| Mahshin, M | 1 |
| Sharma, A | 1 |
| Hossain, MA | 1 |
| Sharma, V | 1 |
| Haque, R | 1 |
| Shamsuzzaman, AKM | 1 |
| Maruf, S | 1 |
| Ghosh, P | 1 |
| Ahuja, V | 1 |
| Mondal, D | 1 |
| Geller, BJ | 1 |
| Mega, JL | 1 |
| Morrow, DA | 1 |
| Guo, J | 1 |
| Hoffman, EB | 1 |
| Gibson, CM | 1 |
| Ruff, CT | 1 |
| Agrawal, A | 1 |
| Gang, TB | 1 |
| Rusiñol, AE | 1 |
| Thiele, JR | 1 |
| Habersberger, J | 1 |
| Braig, D | 1 |
| Schmidt, Y | 1 |
| Goerendt, K | 1 |
| Maurer, V | 1 |
| Bannasch, H | 1 |
| Scheichl, A | 1 |
| Woollard, KJ | 1 |
| von Dobschütz, E | 1 |
| Kolodgie, F | 1 |
| Virmani, R | 1 |
| Stark, GB | 1 |
| Peter, K | 1 |
| Eisenhardt, SU | 1 |
| Rubini Gimenez, M | 1 |
| Pagano, S | 2 |
| Virzi, J | 1 |
| Montecucco, F | 1 |
| Twerenbold, R | 1 |
| Reichlin, T | 1 |
| Wildi, K | 1 |
| Grueter, D | 1 |
| Jaeger, C | 1 |
| Haaf, P | 1 |
| Vuilleumier, N | 2 |
| Mueller, C | 1 |
| Grönlund, H | 1 |
| Hallmans, G | 1 |
| Jansson, JH | 1 |
| Boman, K | 1 |
| Wikström, M | 1 |
| de Faire, U | 1 |
| Frostegård, J | 1 |
| Keller, PF | 1 |
| Roux-Lombard, P | 1 |
| Sigaud, P | 1 |
| Rutschmann, OT | 1 |
| Mach, F | 1 |
| Hochstrasser, D | 1 |
| Sethi, A | 1 |
| Bahekar, A | 1 |
| Bhuriya, R | 1 |
| Bajaj, A | 1 |
| Singh, PP | 1 |
| Arora, R | 1 |
| Khosla, S | 1 |
| Pepys, MB | 1 |
| Hirschfield, GM | 1 |
| Tennent, GA | 1 |
| Gallimore, JR | 1 |
| Kahan, MC | 1 |
| Bellotti, V | 1 |
| Hawkins, PN | 1 |
| Myers, RM | 1 |
| Smith, MD | 1 |
| Polara, A | 1 |
| Cobb, AJ | 1 |
| Ley, SV | 1 |
| Aquilina, JA | 1 |
| Robinson, CV | 1 |
| Sharif, I | 1 |
| Gray, GA | 1 |
| Sabin, CA | 1 |
| Jenvey, MC | 1 |
| Kolstoe, SE | 1 |
| Thompson, D | 1 |
| Wood, SP | 1 |
| Kitsis, RN | 1 |
| Jialal, I | 1 |
| Galli, M | 1 |
| Sommariva, L | 1 |
| Prati, F | 1 |
| Zerboni, S | 1 |
| Politi, A | 1 |
| Bonatti, R | 1 |
| Mameli, S | 1 |
| Butti, E | 1 |
| Pagano, A | 1 |
| Ferrari, G | 1 |
3 reviews available for phosphorylcholine and Myocardial Infarction
| Article | Year |
|---|---|
A Review on Phosphorylcholine-Coated Stents.
Topics: Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Early Ambulation; Heparin Antagonis | 2017 |
Recognition functions of pentameric C-reactive protein in cardiovascular disease.
Topics: Animals; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Complement Activation; Gene E | 2014 |
Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
Topics: Coated Materials, Biocompatible; Confidence Intervals; Coronary Angiography; Coronary Restenosis; Dr | 2012 |
1 trial available for phosphorylcholine and Myocardial Infarction
| Article | Year |
|---|---|
Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.
Topics: Acute Coronary Syndrome; Aged; Antibodies, Antiphospholipid; Factor Xa Inhibitors; Female; Humans; I | 2014 |
11 other studies available for phosphorylcholine and Myocardial Infarction
| Article | Year |
|---|---|
High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction.
Topics: Antigen-Antibody Complex; Apolipoproteins; Autoantibodies; Epitopes; Humans; Immunoglobulin M; Infan | 2023 |
Sphingosylphosphorylcholine alleviates hypoxia-caused apoptosis in cardiac myofibroblasts via CaM/p38/STAT3 pathway.
Topics: Animals; Apoptosis; Calmodulin; Cell Hypoxia; Fibrosis; MAP Kinase Signaling System; Mice, Inbred C5 | 2020 |
Phosphorylcholine antibodies restrict infarct size and left ventricular remodelling by attenuating the unreperfused post-ischaemic inflammatory response.
Topics: Animals; Antibodies, Monoclonal; Apolipoprotein E3; Disease Models, Animal; Female; Inflammation; Is | 2021 |
Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Amphotericin B; Antiprotozoal Agents; Bangladesh; Fema | 2018 |
Dissociation of pentameric to monomeric C-reactive protein localizes and aggravates inflammation: in vivo proof of a powerful proinflammatory mechanism and a new anti-inflammatory strategy.
Topics: Animals; Anti-Inflammatory Agents; Biopolymers; C-Reactive Protein; Carrier Proteins; Cell Adhesion; | 2014 |
Diagnostic and prognostic value of autoantibodies anti-apolipoprotein A-1 and anti-phosphorylcholine in acute non-ST elevation myocardial infarction.
Topics: Aged; Aged, 80 and over; Apolipoprotein A-I; Area Under Curve; Autoantibodies; Case-Control Studies; | 2015 |
Low levels of IgM antibodies against phosphorylcholine predict development of acute myocardial infarction in a population-based cohort from northern Sweden.
Topics: Adult; Aged; Antibodies; Case-Control Studies; Cohort Studies; Down-Regulation; Epitopes; Female; Hu | 2009 |
Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction.
Topics: Aged; Algorithms; Apolipoprotein A-I; Area Under Curve; Autoantibodies; Confidence Intervals; Electr | 2012 |
Targeting C-reactive protein for the treatment of cardiovascular disease.
Topics: Animals; C-Reactive Protein; Cardiovascular Diseases; Complement System Proteins; Drug Design; Hexan | 2006 |
Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein.
Topics: Animals; C-Reactive Protein; Complement Activation; Hexanes; Humans; Myocardial Infarction; Myocardi | 2006 |
Acute and mid-term results of phosphorylcholine-coated stents in primary coronary stenting for acute myocardial infarction.
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Vessels; Endpoint Determination; Female; Follow-Up St | 2001 |